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Abstract  
Patients with biliary strictures often represent a diagnostic and therapeutic challenge, 
due to the site and complexity of biliary obstruction and wide differential diagnosis. 
Multidisciplinary decision making is required to reach an accurate and timely 
diagnosis and to plan optimal care. Developments in endoscopic ultrasound and 
peroral cholangioscopy have advanced the diagnostic yield of biliary endoscopy, and 
novel optical imaging techniques are emerging. Endoscopic approaches to biliary 
drainage are preferred in most scenarios, and recent advances in therapeutic 
endoscopic ultrasound allow drainage where the previous alternatives would have 
only been percutaneous or surgical. Here we review recent advances in endoscopic 
practice for the diagnosis and management of biliary strictures. 
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Introduction 
The accurate diagnosis of biliary strictures based on imaging alone is frequently 
challenging, as there is a wide range of benign and malignant aetiologies (Table 1). 
Due to different management algorithms, these conditions need to be diagnosed 
swiftly and accurately to guide appropriate therapy and optimise outcomes for 
patients. Because of the diagnostic difficulties sometimes encountered, definitive 
treatment such as surgery or chemotherapy may be delayed or given incorrectly, 
with potential consequences for patients. In one study of 238 patients undergoing 
surgical resection of suspected cholangiocarcinoma, 13% were found to have benign 
disease (1). Many of these patients have an autoimmune cholangiopathy (including 
IgG4-related disease) which can be effectively treated with steroids and other 
immunosuppressives. Pathologic confirmation of malignancy can also be 
challenging, and may require endoscopic techniques such as endoscopic ultrasound 
and single operator cholangioscopy. In those with unresectable malignant biliary 
obstruction, effective biliary decompression improves symptoms and enables 
patients to undergo palliative therapies, while in surgical candidates, routine 
preoperative biliary intervention may worsen outcomes. In this review, we outline 
latest innovations in endoscopic techniques for the diagnosis of indeterminate biliary 
strictures and the management of malignant and non-malignant biliary obstruction.  
 
Diagnostics 
 
ERCP with biliary brushings and endoluminal biopsy  
Endoscopic retrograde cholangiopancreatography (ERCP) is a well-established 
technique, typically undertaken after cross-sectional imaging to provide therapy such 
as biliary stent insertion. It allows high-resolution fluoroscopic images to be obtained 
during therapeutic procedures, which provide information on stricture site, length and 
the presence of mucosal irregularity or shouldering (Fig 1). Fluoroscopic stricture 
imaging is able to distinguish malignant from benign strictures with an accuracy of at 
best 80%, so that tissue sampling by biliary brushings or endoluminal biopsies is 
also required (2). Standard ERCP and brush cytology has a variable sensitivity for 
malignancy of 26-73% (pooled sensitivity of 45% in a recent meta-analysis) (3), 
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although this may be improved by techniques such as Fluorescence In Situ 
Hybridisation (FISH) and digital image analysis (4). These techniques allow DNA 
analysis for chromosomal aneuploidy and nuclear DNA content - both of which are 
directly related to the risk of malignancy – and enhance tumour detection by up to 
23% (5,6). A recent systematic review and meta-analysis (SRMA) of eight studies 
involving 828 patients demonstrated that the pooled sensitivity and specificity of 
FISH polysomy to detect cholangiocarcinoma was 51% and 93%, respectively. They 
concluded that whilst FISH was highly specific, the limited sensitivity highlights the 
need for better markers in the early detection of cholangiocarcinoma (4). 
 
Novel imaging techniques, such as narrow-band imaging, autofluorescence, confocal 
laser endomicroscopy and elastic scattering spectroscopy allow augmented views of 
the visualised mucosa during ERCP (7,8). In cases where IgG4-related disease is 
suspected, ampullary biopsies may be diagnostically useful. In one study, ampullary 
biopsies stained positive for IgG4 in 18/27 (67%) symptomatic patients with 
autoimmune pancreatitis, compared with none from patients without the disease (9). 
Additional endoscopic approaches to standard ERCP include endoscopic 
ultrasonography with fine-needle aspiration, intraductal ultrasound or single operator 
cholangioscopy systems (Spyglass, Boston Scientific Corp, Natick, Massachusetts, 
USA), as described below.  
 
Endoscopic ultrasonography  
Endoscopic ultrasound and fine needle aspiration (EUS-FNA) alllows visualisation 
and sampling of the pancreas and biliary tree. EUS-FNA is a standard approach for 
evaluating solid pancreatic masses and is increasingly used in the evaluation of 
biliary strictures. A recent SRMA involving 957 patients reported a pooled sensitivity 
and specificity of 80% and 97% for the diagnosis of cholangiocarcinoma by EUS-
FNA (10). Disadvantages of biliary EUS-FNA include a small risk of tumour seeding. 
In one retrospective study, patients undergoing EUS-FNA prior to liver 
transplantation for perihilar cholangiocarcinoma were more likely to have peritoneal 
metastases at the time of staging laparotomy (83% vs. 8%), although the number of 
patients who underwent EUS-FNA was small (n=16) (11). Peritoneal seeding has not 
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been reported after transduodenal EUS-FNA for distal extrahepatic 
cholangiocarcinoma, where the EUS-FNA tract is resected during 
pancreatoduodenectomy. There have also been isolated case reports of peritoneal 
seeding after EUS-FNA of pancreatic cystic lesions. The PIPE study evaluated the 
frequency of postoperative peritoneal seeding in patients with malignant and non-
malignant intraductal papillary mucinous neoplasm (IPMN) who had undergone 
preoperative EUS-FNA (n = 175) and compared it with that of patients with IPMN 
who had surgery without preoperative EUS-FNA (n = 68). The frequency of 
postoperative peritoneal seeding was similar in the two groups (2.3% vs. 4.4%; p = 
0.403) (12).  
EUS-FNA can be combined with other techniques such as transient elastography 
and contrast agents when assessing pancreatic lesions and lymph nodes, which 
improve the diagnostic accuracy of the technique (13,14) 
 
Intraductal ultrasound 
Intraductal ultrasonography (IDUS) provides real-time, cross-sectional imaging of the 
bile ducts and surrounding structures using a high-frequency ultrasound transducer 
advanced at the time of ERCP. In a retrospective study of 379 patients with 
indeterminate biliary strictures undergoing ERCP, IDUS was able to differentiate 
cholangiocarcinoma from benign strictures with a both a sensitivity and a specificity 
of 98% (15). In a single centre study of 193 patients, IDUS more accurately 
diagnosed proximal than distal ductal strictures (98.1 vs 82.7%, p = 0.006) (16). 
 
Peroral cholangioscopy  
Peroral cholangioscopy with visually targeted biopsies has been reported to have a 
greater diagnostic accuracy than standard ERCP with non-targeted biopsies (17). 
Recent improvements in cholangioscopes have led to a re-emergence of this 
technology. A single operator cholangioscopy system (Spyglass, Boston Scientific 
Corp, Natick, Massachusetts, USA) produces a 6000-pixel fibre optic image and 
enables visually directed intrabiliary biopsies via small disposable forceps. In a 
multicentre, prospective study of 105 patients, the sensitivity and specificity of the 
visual impression of malignancy at cholangioscopy was 90% and 96%, respectively. 
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The sensitivity and specificity of cholangioscopy-guided biopsies for diagnosis of 
malignancy was 85% and 100%, respectively (18). A subsequent SRMA (10 studies, 
n=456) reported a pooled sensitivity and specificity of 66% and 98% for the 
diagnosis of cholangiocarcinoma by cholangioscopic biopsy (19). In the four studies 
where patients had negative or inconclusive brush cytology or intraductal biopsy 
prior to cholangioscopy, the pooled sensitivity and specificity for the diagnosis of 
malignant biliary strictures was 75% and 93%, respectively. Cholangioscopy 
therefore has a particular role when ERCP alone fails to obtain confirmatory cytology 
and the diagnosis remains unclear.  
Several ultra-slim endoscopes have also been developed for cholangioscopy but 
have not been fully validated in prospective trials. In comparison to single operator 
cholangioscopy they are usually placed following standard ERCP, sphincterotomy 
and guidewire cannulation. Procedure times are therefore longer but compared with 
single operator cholangioscopy they enable superior image quality and larger biopsy 
samples of the biliary mucosa (20). 
 
Novel optical techniques  
 
Chromoendoscopy, autofluroscence and narrow-band imaging  
Several techniques have been employed to augment the visualised mucosa during 
cholangioscopy. Biliary narrow-band imaging may assist in delineating tumours and 
distinguishing benign from malignant surface vascular patterns (8). A prospective 
study of 21 patients concluded that narrow-band imaging was significantly better 
than white light at detecting the surface vascular pattern of strictures (p < 0.05) (21). 
Initial cholangioscopic studies with autofluorescence have been less promising; poor 
specificity and high rates of false positivity were observed (7).  
 
Light scattering spectroscopy  
Light scattering spectroscopy (LSS) is a real time in vivo optical technique which 
detects changes in cells, via a probe which is passed through the working channel of 
an endoscope. It enables a field assessment for malignancy via an “optical biopsy”, a 
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potential alternative to standard histology. Perelman et al developed a spatial gating 
fibre-optic probe that is able to rapidly take optical biopsies within pancreatic cysts 
during EUS. In a very recently reported double blind prospective study of 25 patients, 
this technique was able to accurately distinguish neoplastic, mucinous and serous 
lesions, thereby identifying the malignant potential in 21 out of 22 cystic lesions, 
achieving 95% accuracy in the detection of malignancy, compared to 58% accuracy 
for cytology (22). 
 
Confocal laser endomicroscopy  
Confocal laser endomicroscopy (CLE) provides real-time images at the cellular level 
during ERCP and EUS. A “cholangioflex” confocal probe (Mauna Kea Technologies, 
Paris, France) can be placed down a 1.2mm working channel of a cholangioscope or 
the standard channel of a duodenoscope. Following intravenous injection of 
fluorescein, a low-power laser directs light onto a single point on the biliary mucosa. 
Light emanating from this point is focused through a pinhole to a detector. This 
technique produces images which correlate with standard histology and differentiate 
between malignancy, inflammation and normal mucosa. A recent SRMA found CLE 
combined with ERCP demonstrated 90% sensitivity in the assessment of biliary 
strictures (vs 58% for ERCP with biliary brushings plus intraductal biopsies) (23), 
supporting the American Society for Gastrointestinal Endoscopy guidelines that CLE 
is a useful tool for differentiating benign from malignant biliary strictures in patients 
with biliary neoplasia. Small studies have combined CLE with cholangioscopy and 
shown the diagnostic accuracy of the technique can be improved from 78% to 82% 
(23,24). 
 
Therapy  
 
Endoscopic biliary decompression in malignant obstruction 
 
Pre-operative stenting 
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The aims of pre-operative biliary decompression are to improve symptoms and 
hepatic function prior to definitive surgical resection or neo-adjuvant chemotherapy. 
The benefits of pre-operative biliary decompression in patients with resectable 
disease has been debated. In a multicentre trial of 202 patients with pancreatic 
cancer and obstructive jaundice randomised to either early surgery (<1 week from 
randomisation) or pre-operative biliary stenting, serious complications were reported 
in 39% of the early surgery group and 74% in the biliary drainage group (p<0.0001). 
Overall mortality rates were similar in both groups. The authors concluded that pre-
operative biliary drainage is not indicated in patients with a bilirubin <250umol/l (25). 
Other studies have tried to address the issue of whether deeply jaundiced patients 
should undergo pre-operative biliary drainage. In this setting biliary drainage has 
been shown to reduce perioperative and postoperative complications (26). The 
optimal type of stent remains controversial; one recent RCT found no significant 
difference between fully-covered self-expanding metal stents (FCSEMS) vs plastic 
stents (14.2% vs 16.3% re-intervention rate) although the mean interval from 
randomisation to surgery was only 13 days (27). In those patients with a longer 
interval to surgery, such as those receiving neo-adjuvant chemotherapy, FCSEMS 
provide longer patency than plastic stents therefore reducing the need for re-
intervention and minimising interruptions to chemotherapy (28). 
 
Palliative stenting 
In general, self-expanding metal stents (SEMS) are superior to plastic stents in the 
palliative setting. Using SEMS for distal extrahepatic or hilar malignant biliary 
strictures results in significantly longer median patency and lower re-intervention 
rates when compared to plastic stents (29,30). In a recent meta-analysis of 19 
studies involving 1989 patients, SEMS were associated with significantly lower 
occlusion rates, less therapeutic failure (7% vs 13%), less need for re-intervention 
and lower rates of cholangitis (8% vs 21%) than plastic stents (31). Whilst the unit 
cost of  one SEMS exceeds that of a plastic stent, several studies looking into the 
overall cost-effectiveness of SEMS vs plastic stents have concluded that SEMS are 
more cost effective than plastic stents for patients with a life expectancy over four 
months (32). In distal malignant biliary obstruction there is a choice between 
FCSEMS and uncovered SEMS, each with their own advantages and 
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disadvantages. A recent meta-analysis comparing the two groups found the 
FCSEMS cohort to have a lower incidence of adverse events (OR: 0.74, 95% CI: 
0.57 to 0.97, P = 0.03) with no difference in stent dysfunction, stent patency or 
patient survival (33). 
 
Stenting of malignant hilar strictures 
Intrinsic or extrinsic compression of the biliary tree at the liver hilum can lead to 
disconnection of the right and left systems. Hilar strictures are classified according to 
the Bismuth-Corlette classification. To relieve clinical jaundice, it is estimated that at 
least one third of the liver should be drained. Initial options for drainage include 
endoscopic, percutaneous or surgical approaches. Several studies have attempted 
to define optimal stenting practice based on cross sectional imaging in this setting. 
The majority of patients with malignant hilar strictures have non-resectable disease. 
In those with a predicted survival of greater than four months, uncovered SEMS are 
superior to plastic stents for palliation with respect to outcome and cost-effectiveness 
(34). Adequate biliary drainage can generally be achieved with unilateral, bilateral 
side-by-side or bilateral stent-in-stent approaches, with evidence currently lacking as 
to which of these approaches is optimal (Fig 2) (34). In patients with potentially 
resectable hilar cholangiocarcinoma, several RCTs and meta-analyses have 
evaluated the utilty of pre-operative biliary drainage in this group (35), the results 
showing significantly higher post-operative morbidity in the drained vs undrained 
groups (OR 1.67: 95% CI), therefore routine pre-operative stenting in hilar 
cholangiocarcinoma is not recommended (34).  
 
Endoscopic biliary decompression in benign obstruction 
Important aetiologies of benign biliary strictures include post-surgical bile duct injury, 
chronic pancreatitis, primary sclerosing cholangitis (PSC) and IgG4-related disease. 
Of these, post-cholecystectomy bile duct injury (0.5% incidence) and post-liver 
transplant anastomotic strictures (10-40% incidence) are the most common 
aetiologies (36,37). The treatment goals in managing benign biliary strictures are to 
relieve obstruction, maintain ductal patency and restore liver function. Data suggests 
that endoscopic therapy for benign biliary strictures is safe, effective and less 
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invasive than surgical approaches (38), so that it is the first line therapeutic option in 
most patients with an accessible papilla (39). 
Standard therapeutic approaches to benign strictures includes balloon dilation, 
insertion of multiple plastic stents with stent change each 3-4 months (up to 12 
months) or remodelling the stricture through FCSEMS placement for 3-6 months. 
The last of these options has been shown to be safe, effective, technically 
straightforward and associated with fewer procedures (39). In a recent international 
prospective study of 177 patients with benign biliary strictures who underwent 
temporary FCSEMS placement, all stents were successfully removed without 
complication and stricture resolution was achieved in 76.3% of patients (40).  
Biliary stricture dilatation can be performed with either a balloon or bougie, although 
early dilatation of post-surgical strictures (<4 weeks) may be associated with bile 
leak (41). Balloon dilatation alone without subsequent stenting is associated with a 
high rate of stricture recurrence in anastomotic strictures and chronic pancreatitis 
(41). The exception is dominant strictures in PSC where repeated balloon dilatations 
without stent placement is associated with improved long-term outcomes (42). 
Gotthardt et al prospectively studied 101 PSC patients with dominant strictures 
treated with either balloon dilatation or stenting. Long term follow-up showed 
excellent rates of bile duct patency with 5-year transplant-free and 10-year 
transplant-free survival rates of 81% and 52%, respectively (42). For patients with 
IgG4-related biliary strictures stenting is not recommended unless there is severe 
jaundice or cholangitis, in which case a stent may bridge the patient until steroid 
response (43).  
Placement of uncovered SEMS in benign biliary strictures or indeterminate strictures 
is usually contraindicated due to the likelihood of tissue ingrowth and subsequent 
stent embedment (39). 
 
Alternative biliary drainage options if ERCP fails  
 
Percutaneous transhepatic drainage (PTD) 
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Endoscopic drainage, particularly of hilar strictures, can be challenging and PTD with 
stent placement provides an alternative method of biliary decompression. PTD is 
used for both hilar cholangiocarcinoma where it allows for selective duct drainage 
and in cases of failed endoscopic access due to gastric outlet obstruction, duodenal 
indwelling stents, or surgically altered anatomy such as Roux-en-Y 
hepaticojejunostomy (44). 
 
Endoscopic ultrasound-guided biliary drainage  
When ERCP fails, endoscopic ultrasound-guided biliary puncture from the 
duodenum or stomach is an alternative approach with outcomes similar to 
percutaneous drainage. Passage of a guidewire through the tract enables standard 
cannulation and stent placement via a ‘rendezvous’ technique, or alternatively a 
stent can be placed across the tract to allow bile to drain directly into the duodenum 
or stomach. EUS-guided biliary drainage (EUS-BD) is a novel technique for patients 
who have failed endoscopic biliary stenting and may be considered as an alternative 
to PTD. In expert hands, success rates have been shown to be above 90% with 
rates of adverse events 17% (45). A recent SRMA (9 studies, 483 patients) 
compared EUS-BD with PTD. They concluded that whilst there was no difference in 
technical success, EUS-BD was associated with higher rates of clinical success, less 
adverse events and lower rates of re-intervention. EUS-BD was also more cost 
effective (46). 
 
Surgical bypass  
Historically biliary decompression has been achieved through surgical biliary bypass 
procedures. A recent meta-analysis reported less recurrent biliary obstruction after 
surgical bypass when compared with endoscopic biliary stenting in the management 
of malignant biliary obstruction. Technical success rates and complication rates were 
also similar (47). Surgical bypass is only suitable for surgically fit candidates, limiting 
its use in advanced cancer.  
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Novel endoscopic approaches to therapy  
Patients with inoperable cholangiocarcinoma and pancreatic cancer have an 
extremely poor prognosis. Meta-analyses have not shown significant improvement 
with standard chemoradiation regimens (48), likely due to an advanced tumour stage 
at presentation coupled with aggressive tumour biology. However, two novel 
endoscopic interventions have shown promise in early studies: Photodynamic 
therapy (PDT) and radiofrequency ablation (RFA). 
 
Photodynamic therapy 
Photodynamic therapy (PDT) is an ablative technique involving intravenous 
administration of a photosensitising agent followed by endoscopic intraluminal laser 
irradiation. The agent concentrates within the tumour cells and once activated by the 
light of the laser generates reactive oxygen species. These cause photodamage of 
intracellular structures and cell membranes leading to tumour cell apoptosis and 
necrosis. A previous randomised controlled trial of PDT when compared to biliary 
stenting alone showed a significant increase in survival time from 98 d to 493 d (49), 
with another RCT showing median survival increasing from 210 to 630 d (50). 
Retrospective data also contributes to the body of information supporting increased 
survival and quality of life when PDT is used in addition to biliary stents as well as 
chemotherapy (51,52). The high cost of PDT may be a factor preventing its 
widespread use for local control of unresectable cholangiocarcinoma. 
 
Radiofrequency ablation 
Endoscopic Radiofrequency Ablation (RFA) is a palliative locoregional treatment that 
can be used in malignant biliary obstruction either as a first line treatment to improve 
the bile duct diameter or to treat tumour ingrowth of uncovered stents (53). A 
catheter inserted into the biliary tree delivers a therapeutic heating zone leading to 
coagulation necrosis of the tumour. After treatment, a stent is usually 
placed. Evidence for the use of endoscopic RFA is restricted to retrospective 
analyses and small prospective cohort studies (54). A recent retrospective 
comparison of PDT vs RFA in the palliation of malignant biliary strictures compared 
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results in 48 patients (16 RFA, 32 PDT) demonstrating similar median survival (9.6 
mo in RFA, 7.5 mo in PDT) (55). 
 
Conclusion  
The re-emergence of peroral cholangioscopy alongside several other novel 
diagnostic techniques has led to improvements in the diagnostic accuracy of 
endoscopic assessment of indeterminate biliary strictures. Further evaluation of 
these new techniques will define their place in diagnostic and management 
algorithms for patients with biliary strictures. Improvements in the range of biliary 
access techniques, endobilary stents and novel ablative treatments along with local 
therapies have led to significant improvements in the palliation of pancreaticobiliary 
malignancy.   
 
Abbreviations: 
CC  Cholangiocarcinoma 
CLE  Confocal Laser Endomicroscopy 
ERCP  Endoscopic Retrograde Cholangiopancreatography 
EUS-FNA  Endoscopic Ultrasound-Fine Needle Aspiration 
FCSEMS Fully-covered Self-expanding Metal Stent 
FISH  Fluorescence in situ Hybridisation 
IDUS  Intraductal Ultrasound 
PDT  Photodynamic Therapy 
PTD  Percutaneous Transhepatic Drainage 
RFA  Radiofrequency Ablation 
SEMS  Self-expanding Metal Stent 
SRMA   Systematic Review and Meta-Analysis 
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TABLES AND FIGURES 
 
Table 1. Differential diagnosis of indeterminate biliary stricture. 
 
Prognosis Condition 
Benign Post-operative (following laparoscopic cholecystectomy or biliary 
anastomosis) 
Chronic pancreatitis 
Primary sclerosing cholangitis 
Autoimmune cholangiopathy, IgG4 sclerosing-cholangitis 
Post-radiotherapy 
Infections (TB, histoplasmosis, viral, parasitic, HIV cholangiopathy) 
Choledocholithiasis / Mirrizzi syndrome 
Vasculitis 
Trauma 
Ischaemia 
Post biliary sphincterotomy 
Extraluminal compression (lymph nodes, vascular) 
Malignant Cholangiocarcinoma 
Pancreatic cancer 
Metastatic disease 
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Figure 1. Endoscopic evaluation and treatment of an extra-hepatic biliary stricture 
due to a pancreatic mass lesion: A. Fluoroscopic view of distal common bile duct 
stricture with double-duct sign; B. Fluoroscopic view of fully-covered self-expanding 
metal biliary stent. C. Endoscopic view of biliary stent.  
 
 
 
Figure 2. Endoscopic assessment and treatment of a malignant hilar stricture: A. 
Fluoroscopic view of malignant hilar stricture; B. Fluoroscopic image after insertion of 
bilateral uncovered metal biliary stents; C. Endoscopic view of the biliary stents. 
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